Skip to Content
Merck

Key Documents

View All Documentation

EZHS40

Millipore

Human Amyloid β40 ELISA Kit

measures and quantifies Amyloid β40 levels in 50 μL CSF, cell culture supernatent or plasma

Synonym(s):

Amyloid-beta protein 40

Sign Into View Organizational & Contract Pricing

Select a Size

All Photos(1)

About This Item

UNSPSC Code:
12161503
eCl@ss:
32161000
NACRES:
NA.84

Product Name

High Sensitivity Human Amyloid β40 ELISA, This High Sensitivity Human Amyloid β40 ELISA is used to measure & quantify Amyloid β40 levels in Neuroscience research.

Quality Level

200

species reactivity

human

packaging

kit of 1 × 96 wells

parameter

50 μL sample volume (Overnight assay)

assay range

sensitivity: 6.0 pg/mL
(50 μl sample size)
standard curve range: 16-500 pg/mL

technique(s)

ELISA: suitable

input

sample type plasma (K2 EDTA)
sample type serum
sample type cerebrospinal fluid (CSF)

application(s)

research use

detection method

colorimetric (450nm/590nm)

shipped in

wet ice

storage temp.

2-8°C

Gene Information

human ... APP(351)

General description

Amyloid beta peptides have been implicated in the etiology of Alzheimer’s disease. Amyloid beta 40 is the most prominent peptide and Amyloid beta 42 is the neurotoxic form. The Amyloid beta 42/40-ratio (AB ratio) has been reported as a better indicator of the Alzheimer pathology. Millipore’s High Sensitivity Human Amyloid β40 ELISA kit is used for the measurement of Amyloid β40 in cerebrospinal fluid, cell culture supernatants, primary neurons and plasma in a 96-well format.

Application

Research Category
Neuroscience
Research Sub Category
Alzheimer′s Disease
This High Sensitivity Human Amyloid β40 ELISA is used to measure & quantify Amyloid β40 levels in Neuroscience research.
This assay requires 50 µl of sample (cerebrospinal fluid, cell culture supernatants, primary neurons, or plasma) and is an overnight assay.
Used to detect/quantify: Amyloid β40

Biochem/physiol Actions

The Amyloid β40 ELISA (HS) uses monoclonal anti-Aβ antibodies with high selectivity for human Aβ. The capture antibody recognizes the C-terminal end of Amyloid β1-40, which causes a high selectivity for Aβ 40. The cross-reactivity of the used antibodies to other Amyloid peptides was tested by ELISA and BIACORE and shows no significant cross-reactivity to Aβ1-38, Aβ1-39, Aβ1-42, Aβ1-43 and Aβ1-44.

Preparation Note

Components in the kit can be stored up to 2 weeks at 2-8°C

Other Notes

Please contact Technical Service for linearity of dilution.

Disclaimer

For research use only. Not for use in diagnostic procedures.

Pictograms

CorrosionExclamation mark
GHS05,GHS07

Signal Word

Warning

Hazard Statements

H290,H317,H412

Hazard Classifications

Aquatic Chronic 3 - Met. Corr. 1 - Skin Sens. 1

Storage Class Code

8A - Combustible corrosive hazardous materials

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Kendra L Puig et al.
Journal of Alzheimer's disease : JAD, 44(4), 1263-1278 (2014-11-20)
Alzheimer's disease (AD) is a neurodegenerative disorder histologically characterized by amyloid-β (Aβ) protein accumulation and activation of associated microglia. Although these features are well described in the central nervous system, the process and consequences of Aβ accumulation in the enteric
Gunjan Manocha et al.
Current Alzheimer research, 15(12), 1123-1135 (2018-08-03)
Alzheimer's disease (AD) is associated with age-associated central nervous system degeneration and dementia. This decline in the function correlates with deposition of Aβ peptide containing plaques and associated reactive gliosis. The inflammatory phenotype of microglia, in particular, is often considered
Anna Bogstedt et al.
Journal of Alzheimer's disease : JAD, 46(4), 1091-1101 (2015-09-25)
Utilizing decision making biomarkers in drug development requires thorough assay validation. Special considerations need to be taken into account when monitoring biomarkers using immunoassays in the presence of therapeutic antibodies. We have developed robust and sensitive assays to assess target
Nataliya Golovyashkina et al.
Molecular neurodegeneration, 10, 60-60 (2015-11-07)
Dendritic simplification, a key feature of the neurodegenerative triad of Alzheimer's disease (AD) in addition to spine changes and neuron loss, occurs in a region-specific manner. However, it is unknown how changes in dendritic complexity are mediated and how they
Mariya V Hrynchak et al.
Frontiers in synaptic neuroscience, 12, 16-16 (2020-05-12)
Alzheimer's disease is regarded as a synaptopathy with a long presymptomatic phase. Soluble, oligomeric amyloid-β (Aβ) is thought to play a causative role in this disease, which eventually leads to cognitive decline. However, most animal studies have employed mice expressing
View All Related Papers

Global Trade Item Number

SKUGTIN
EZHS4004053252328282

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service